ArticleJournal of gastrointestinal cancer2021

Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.

Kazuma Kobayashi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.